The results in our work, however, have identified, for the first time, a high-risk PC cohort, encompassing patients with localised and metastatic prostate cancer that could benefit from treatment with an anti-CD3 ×  PSMA bispecific engager. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.